Dogwood Therapeutics, Inc. Common Stock (DWTX) Stock Price

DWTXStock
$1.22−79.70%52W
Market Cap$41.47M
P/E—
PEG Ratio—
Div yield—
Beta2.15

DWTX Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-41.75%
Price vs S&P 500 (4W)-22.42%
VGM Score37.30

DWTX Earnings Surprise History

QuarterReport dateEPS estimateEPS actualSurprise
Q2 2026-$0.14-$0.34-148.77%(-$0.20)
Q1 2026-$0.20-$0.15+25.00%(+$0.05)
Q4 2025-$0.86-$0.26+69.77%(+$0.60)
Q3 2025-$1.58-$8.20-417.90%(-$6.62)
Q2 2025-$1.90-$1.99-4.74%(-$0.09)

DWTX Analyst Recommendations

Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.13
4.13
4.13
4.13

Industry Peers — Pharmaceuticals(574)

SymbolValue ScoreGrowth ScoreMomentum ScoreP/S Ratio (TTM)Revenue Growth TTM (YoY)Gross Margin (TTM)EPS Growth (5Y)Price
DWTXDogwood Therapeutics, Inc. Common Stock
——D————$1.22
LLYEli Lilly & Co.DBA14.9x49.6%83.4%27.6%$1257.03
JNJJohnson & JohnsonDCB6.2x7.8%67.7%14.9%$255.56
ABBVABBVIE INC.DCA7.8x10.4%72.8%-2.9%$285.42
MRKMerck & Co., Inc.DCA5.4x4.6%77.3%21.2%$145.95
NVSNovartis AGCCB4.9x3.3%75.0%15.3%$150.62
AZNAstraZeneca PLCCBB4.3x8.6%81.3%21.9%$165.41
ABTAbbott LaboratoriesCCB3.9x8.1%56.8%8.2%$104.89
NVONovo-Nordisk A/SBCC3.5x5.6%80.7%20.7%$38.83
PFEPfizer Inc.CDA2.6x-0.2%74.7%-3.5%$29.58
VRTXVertex Pharmaceuticals IncDCB10.1x10.2%86.0%8.3%$499.74

About Dogwood Therapeutics, Inc. Common Stock

Dogwood Therapeutics (formerly Virios Therapeutics) is a development-stage biotech company developing antiviral therapies for conditions associated with abnormal viral-triggered immune responses, including fibromyalgia and long COVID. Its lead candidates—IMC-1, which targets Epstein-Barr virus replication, and IMC-2, a combination of valacyclovir and celecoxib—address the underlying immune dysfunction believed to drive these conditions.